Highlight
The phase 3 SatraGO-1 and SatraGO-2 randomized trials evaluated satralizumab, an anti-interleukin-6 receptor antibody, in patients with active and inactive thyroid eye disease (TED). At 24 weeks, satralizumab resulted in significant improvements in proptosis reduction, clinical activity scores, and diplopia compared to placebo. The drug demonstrated a favorable safety and tolerability profile, underscoring the therapeutic potential of IL-6 pathway inhibition in TED management.
